Trial Profile
CALIBRATION: An Exploratory Study in Patients With Advanced Oesophageal Malignancies Receiving MEDI4736 (Durvalumab), Investigating Whether Early Changes in Circulating Tumour DNA Can Predict Tumour Response
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms CALIBRATION
- 09 Feb 2023 Planned End Date changed from 1 Feb 2022 to 1 Jun 2024.
- 21 Sep 2020 Interim data results (n=7) presented at the 45th European Society for Medical Oncology Congress
- 01 Oct 2019 Trial design results presented at the 44th European Society for Medical Oncology Congress.